RB nr 1/2009

Legal basis: art. § 5 ust. 1 pkt 1 RO oraz § 7 RO

The Management Board of MCI Management SA informs that on December 30, 2008 MCI.BioVentures Sp. z o.o. – a subsidiary of MCI Management SA – paid in the capital to acquire 582 (five hundred eighty two) new shares of the nominal value of PLN 50 (fifty) at PLN 2,750 (two thousand seven hundred fifty) per each share. As a result of the acquisition of newly crated 582 MCI.BV shall hold 22.54% of the shares in the share capital of the Company and the same amount of votes at the General Meeting of the Shareholders of the Company or at the General Assembly of the Shareholders of the Company after the transformation of the Company into a joint stock company.
The transaction was executed in connection of the fulfillment of the conditions of the investment agreement concluded between MCI.BioVentures and ForMed on Dec. 10, 2008 and it complies with the planned execution of the 1st round of financing.

ForMed is a company whose operations include creating medical centers operating in the medium price segment financed to a large extent on the basis of membership and cooperation with insurers as well as providing membership medical services consisting in comprehensive medical care.
MCI.BioVentures is a seed capital fund investing up to EUR 1 million in companies operating in the sector of biotechnology, new drugs and healthcare in Poland. The funds of the fund shall be spent on investments in companies in their early stage of development.

This is a long-term investment. There are no connections referred to in § 7 subpar. 6 of RO. The purchased assets represent over 20% of the share capital of ForMed Sp. z o.o. and are considered assets of considerable value.